Literature DB >> 23900766

Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.

J T Sandlund1, M M Hudson, W Kennedy, M Onciu, M B Kastan.   

Abstract

Children with ataxia-telangiectasia (A-T) and cancer have a poorer prognosis due in part to increased treatment-related toxicity. We piloted a curative intent approach in five children with A-T who presented with advanced stage (III, n = 2; IV, n = 3) B-NHL (diffuse large B-cell lymphoma, n = 4; Burkitt leukemia, n = 1) using a modified LMB-based protocol. Two achieved sustained CCR (one, CCR at 6 years; one, pulmonary death after 3 years in CCR). Two died from toxicity during induction and 1 failed induction with progressive disease. Novel therapeutic approaches which overcome drug resistance and are less toxic are needed for children with A-T and B-NHL.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hodgkin lymphoma; ataxia-telangiectasia; children; non-Hodgkin lymphoma

Mesh：

Substances：

Year:  2013        PMID： 23900766      PMCID： PMC4254821          DOI： 10.1002/pbc.24696

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  20 in total

1.  Severe lung fibrosis after chemotherapy in a child with ataxia-telangiectasia.

Authors:  Rong-Long Chen; Pen-Jung Wang; Yung-Hsiung Hsu; Pau-Yuan Chang; Jye-Siung Fang
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

2.  Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.

Authors:  Gabriele Rossi; Marco Zecca; Antonietta Marchi; Piero de Stefano; Luigi Sammarchi; Franco Locatelli
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

3.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

4.  Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature.

Authors:  E M Sillos; J L Shenep; G A Burghen; C H Pui; F G Behm; J T Sandlund
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

5.  Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.

Authors:  Klaus Bienemann; Birgit Burkhardt; Simon Modlich; Ulrike Meyer; Anja Möricke; Kirsten Bienemann; Christine Mauz-Körholz; Gabriele Escherich; Martin Zimmermann; Dieter Körholz; Gritta Janka-Schaub; Martin Schrappe; Alfred Reiter; Arndt Borkhardt
Journal:  Br J Haematol       Date:  2011-09-19       Impact factor: 6.998

6.  Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults.

Authors:  S B Murphy
Journal:  Semin Oncol       Date:  1980-09       Impact factor: 4.929

7.  The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.

Authors:  C Patte; A Auperin; J Michon; H Behrendt; G Leverger; D Frappaz; P Lutz; C Coze; Y Perel; M Raphaël; M J Terrier-Lacombe
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

8.  Interstitial lung disease in patients with ataxia-telangiectasia.

Authors:  Scott A Schroeder; Michael Swift; Claudio Sandoval; Claire Langston
Journal:  Pediatr Pulmonol       Date:  2005-06

9.  Treatment of lymphoid malignancies in patients with ataxia-telangiectasia.

Authors:  C Sandoval; M Swift
Journal:  Med Pediatr Oncol       Date:  1998-12

10.  Immunodeficiency and infections in ataxia-telangiectasia.

Authors:  Anna Nowak-Wegrzyn; Thomas O Crawford; Jerry A Winkelstein; Kathryn A Carson; Howard M Lederman
Journal:  J Pediatr       Date:  2004-04       Impact factor: 4.406
View more
  10 in total

1.  Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.

Authors:  Hikmet G Tanyildiz; Handan Dincaslan; Gulsan Yavuz; Emel Unal; Aydan Ikinciogulları; Figen Dogu; Nurdan Tacyildiz
Journal:  J Clin Immunol       Date:  2016-08-04       Impact factor: 8.317

2.  T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:  Geling Li; Emily Waite; Julie Wolfson
Journal:  Blood Adv       Date:  2017-12-18

3.  International Pediatric Non-Hodgkin Lymphoma Response Criteria.

Authors:  John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

Review 4.  Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Authors:  Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

5.  Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.

Authors:  Andishe Attarbaschi; Elisa Carraro; Oussama Abla; Shlomit Barzilai-Birenboim; Simon Bomken; Laurence Brugieres; Eva Bubanska; Birgit Burkhardt; Alan K S Chiang; Monika Csoka; Alina Fedorova; Janez Jazbec; Edita Kabickova; Zdenka Krenova; Jelena Lazic; Jan Loeffen; Georg Mann; Felix Niggli; Natalia Miakova; Tomoo Osumi; Leila Ronceray; Anne Uyttebroeck; Denise Williams; Wilhelm Woessmann; Grazyna Wrobel; Marta Pillon
Journal:  Haematologica       Date:  2016-08-11       Impact factor: 9.941

Review 6.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

Review 7.  Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group.

Authors:  Simon Bomken; Jutte van der Werff Ten Bosch; Andishe Attarbaschi; Chris M Bacon; Arndt Borkhardt; Kaan Boztug; Ute Fischer; Fabian Hauck; Roland P Kuiper; Tim Lammens; Jan Loeffen; Bénédicte Neven; Qiang Pan-Hammarström; Isabella Quinti; Markus G Seidel; Klaus Warnatz; Claudia Wehr; Arjan C Lankester; Andrew R Gennery
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561

8.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

Review 9.  Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

Authors:  Agata Pastorczak; Andishe Attarbaschi; Simon Bomken; Arndt Borkhardt; Jutte van der Werff Ten Bosch; Sarah Elitzur; Andrew R Gennery; Eva Hlavackova; Arpád Kerekes; Zdenka Křenová; Wojciech Mlynarski; Tomasz Szczepanski; Tessa Wassenberg; Jan Loeffen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

10.  Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8.

Authors:  Mariana T De Souza; Gabriela Vera-Lozada; Moneeb Othman; Teresinha J Marques-Salles; Luciana W Pinto; Moisés M da Rocha; Soraia Rouxinol; Thomas Liehr; Raul C Ribeiro; Rocio Hassan; Maria Luiza M Silva
Journal:  Ann Lab Med       Date:  2018-01       Impact factor: 3.464
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.